Brokerages Expect Inovio Pharmaceuticals Inc (INO) to Announce -$0.20 Earnings Per Share

Share on StockTwits

Wall Street brokerages expect Inovio Pharmaceuticals Inc (NASDAQ:INO) to post ($0.20) earnings per share (EPS) for the current quarter, Zacks Investment Research reports. Three analysts have issued estimates for Inovio Pharmaceuticals’ earnings. The lowest EPS estimate is ($0.29) and the highest is ($0.07). Inovio Pharmaceuticals posted earnings per share of ($0.08) in the same quarter last year, which would indicate a negative year-over-year growth rate of 150%. The company is scheduled to announce its next earnings results on Tuesday, August 6th.

On average, analysts expect that Inovio Pharmaceuticals will report full-year earnings of ($0.99) per share for the current financial year, with EPS estimates ranging from ($1.01) to ($0.93). For the next fiscal year, analysts anticipate that the company will post earnings of ($1.05) per share, with EPS estimates ranging from ($1.22) to ($0.93). Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side research firms that cover Inovio Pharmaceuticals.

Inovio Pharmaceuticals (NASDAQ:INO) last issued its earnings results on Thursday, May 9th. The biopharmaceutical company reported ($0.30) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.01). The business had revenue of $2.83 million during the quarter, compared to analyst estimates of $4.44 million. Inovio Pharmaceuticals had a negative net margin of 295.24% and a negative return on equity of 97.95%.

A number of equities analysts recently commented on INO shares. HC Wainwright set a $13.00 price objective on Inovio Pharmaceuticals and gave the stock a “buy” rating in a report on Monday, April 22nd. Zacks Investment Research raised Inovio Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, March 15th. Cantor Fitzgerald assumed coverage on Inovio Pharmaceuticals in a research note on Monday, March 25th. They issued an “overweight” rating and a $3.62 price objective for the company. BidaskClub raised Inovio Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Wednesday, March 27th. Finally, Maxim Group set a $8.00 price objective on Inovio Pharmaceuticals and gave the stock a “buy” rating in a research note on Wednesday, February 20th. Two equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $7.57.

Shares of INO traded down $0.05 during trading hours on Wednesday, reaching $3.49. The company’s stock had a trading volume of 33,622 shares, compared to its average volume of 850,671. The company has a market capitalization of $349.98 million, a price-to-earnings ratio of -3.31 and a beta of 1.70. Inovio Pharmaceuticals has a 1-year low of $3.02 and a 1-year high of $6.30. The company has a debt-to-equity ratio of 1.02, a current ratio of 4.92 and a quick ratio of 4.92.

Institutional investors have recently modified their holdings of the company. SG Americas Securities LLC purchased a new stake in shares of Inovio Pharmaceuticals in the first quarter worth approximately $40,000. Quantamental Technologies LLC purchased a new stake in shares of Inovio Pharmaceuticals during the fourth quarter valued at approximately $43,000. Amalgamated Bank purchased a new stake in shares of Inovio Pharmaceuticals during the fourth quarter valued at approximately $50,000. Pembroke Management LTD purchased a new stake in shares of Inovio Pharmaceuticals during the fourth quarter valued at approximately $52,000. Finally, Fox Run Management L.L.C. purchased a new stake in shares of Inovio Pharmaceuticals during the fourth quarter valued at approximately $58,000. 40.50% of the stock is owned by hedge funds and other institutional investors.

About Inovio Pharmaceuticals

Inovio Pharmaceuticals, Inc, a late-stage biotechnology company, focuses on the discovery, development, and commercialization of DNA-based immunotherapies and vaccines to prevent and treat cancers and infectious diseases. Its SynCon immunotherapy design has the ability to break the immune system's tolerance of cancerous cells, as well as is intended to facilitate cross-strain protection against known, as well as new unmatched strains of pathogens, such as influenza.

Featured Article: What is the Federal Reserve?

Get a free copy of the Zacks research report on Inovio Pharmaceuticals (INO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Inovio Pharmaceuticals (NASDAQ:INO)

Receive News & Ratings for Inovio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Brokerages Expect Inovio Pharmaceuticals Inc  to Announce -$0.20 Earnings Per Share
Brokerages Expect Inovio Pharmaceuticals Inc to Announce -$0.20 Earnings Per Share
Pinduoduo  Shares Gap Up to $22.15
Pinduoduo Shares Gap Up to $22.15
Equity Lifestyle Properties, Inc.  Receives $106.70 Consensus Target Price from Analysts
Equity Lifestyle Properties, Inc. Receives $106.70 Consensus Target Price from Analysts
Scroll  Price Tops $0.12
Scroll Price Tops $0.12
Brokerages Set Cott Corp  PT at $18.80
Brokerages Set Cott Corp PT at $18.80
Cloudbric  Market Cap Reaches $1.75 Million
Cloudbric Market Cap Reaches $1.75 Million


© 2006-2019 Ticker Report